Bristol Myers Squibb (NYSE:BMY) Issues Earnings Results, Beats Estimates By $0.25 EPS

Bristol Myers Squibb (NYSE:BMY) released its quarterly earnings results on Thursday. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.25, FiscalAI reports. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The business had revenue of $13.07 billion during the quarter, compared to analysts’ expectations of $12.72 billion. During the same period in the prior year, the business posted $1.63 EPS. The company’s revenue was up 6.9% compared to the same quarter last year.

Here are the key takeaways from Bristol Myers Squibb’s conference call:

• Strong third-quarter execution led to raised 2026 guidance. Revenue increased 7% to approximately $13.1 billion, growth-portfolio sales rose 12%, and non-GAAP EPS guidance is now $6.35–$6.55.
• The growth portfolio is becoming increasingly diversified, with eight medicines each annualizing above $1 billion. Key contributors included BREYANZI, CAMZYOS, OPDUALAG, REVLIMID, and QVANTIG, whose sales grew 28% sequentially and are now annualizing above $1.3 billion.
• BMS reported encouraging pipeline progress, including positive registrational results for Zenbexus, admilparant, RYZ101, and arlo-cel. The company also expects multiple additional readouts through 2027, including milvexian, SOTYKTU in lupus, Cobenfy, and golcadomide.
• The company expects a significant $1.5 billion–$2 billion ELIQUIS revenue decline in 2027 as loss of exclusivity begins in Europe, while the broader legacy portfolio is expected to decline 3%–5% in 2026.
• Management highlighted execution risks and ongoing uncertainty around several programs, including mixed dose results for admilparant, the need to improve Cobenfy patient starts and repeat prescribing, and a temporary clinical pause for autoimmune CAR-T candidate zola-cel following a fatal septic pneumonia case.

Bristol Myers Squibb Stock Performance

Shares of NYSE:BMY traded up $1.37 during midday trading on Friday, hitting $62.76. The stock had a trading volume of 3,937,676 shares, compared to its average volume of 12,002,315. Bristol Myers Squibb has a 1 year low of $45.20 and a 1 year high of $68.64. The stock has a 50 day moving average price of $62.86 and a two-hundred day moving average price of $59.90. The company has a market capitalization of $128.21 billion, a PE ratio of 13.82, a P/E/G ratio of 0.31 and a beta of 0.19. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be paid a dividend of $0.63 per share. The ex-dividend date is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Third-quarter adjusted earnings of $1.35 per share exceeded the $1.10 consensus estimate, while revenue rose 6.9% year over year to $13.07 billion, topping expectations of $12.72 billion. Bristol-Myers Squibb Q3 earnings flash
• Positive Sentiment: Bristol Myers raised its 2026 revenue outlook to approximately $50 billion as its Growth Portfolio—including newer drugs such as Camzyos, Reblozyl and Breyanzi—expanded 12% to $7.7 billion. The newer products offset pressure from patent expirations affecting older medicines. Bristol Myers raises full-year revenue guidance
• Positive Sentiment: Management highlighted progress across its development pipeline, including oncology programs and the use of artificial intelligence to accelerate drug research. Barclays also maintained its Buy rating, supporting investor confidence in the company’s longer-term growth strategy. Barclays maintains Buy rating
• Neutral Sentiment: The revenue outlook increase largely reflects stronger newer-drug sales rather than broad-based growth. Investors will continue watching whether the Growth Portfolio can replace revenue lost to patent expirations and support sustained expansion. BMY Q3 earnings call highlights
• Negative Sentiment: Adjusted EPS declined from $1.63 a year earlier, and Bristol Myers cut its 2026 EPS outlook because of higher in-process research and development charges. Opdivo sales also came in below expectations, while patent losses and challenges launching new products remain risks. The caveat behind Bristol Myers’ sales guidance boost

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Truist Financial set a $70.00 price target on shares of Bristol Myers Squibb in a research note on Friday. Bank of America reissued a “buy” rating on shares of Bristol Myers Squibb in a report on Friday. Argus upgraded Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target on the stock in a research note on Wednesday, August 5th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Finally, TD Cowen initiated coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $65.50.

Insider Activity at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.